BAWEI
837023
XI'AN WONDER
836419
Jiangsu Tiangong Technology
920068
4
Fujian Green Pine
300132
5
Yili Chuanning Biotechnology
301301
CN Stock MarketDetailed Quotes
688767 Hangzhou Biotest Biotech
- 43.32
- -0.83-1.88%
Market Closed May 15 15:00 CST
4.62BMarket Cap33.32P/E (TTM)
44.48High43.20Low6.59KlotVolume44.16Open44.15Pre Close28.71MTurnover0.62%Turnover Ratio27.26P/E (Static)106.67MShares44.6052wk High1.91P/B4.62BFloat Cap22.8852wk Low52.98Limit Up106.67MShs Float146.02Historical High35.32Limit Down2.90%Amplitude20.95Historical Low1.30Dividend TTM43.57Avg Price3.72KlotAsk3.00%Div YieldTTM100Lot Size2.34KlotBid
Hangzhou Biotest Biotech Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -35.20%87.89M | 26.53%559.4M | 24.51%388.78M | 25.97%267.16M | 30.81%135.63M | -76.75%442.11M | -82.23%312.24M | -86.08%212.08M | -89.81%103.69M | 4.57%1.9B |
| Operating revenue | -35.20%87.89M | 26.53%559.4M | 24.51%388.78M | 25.97%267.16M | 30.81%135.63M | -76.75%442.11M | -82.23%312.24M | -86.08%212.08M | -89.81%103.69M | 4.57%1.9B |
| Total operating cost | -10.10%81.93M | 20.87%361.38M | 32.77%287.4M | 28.16%181.87M | -1.03%91.14M | -68.55%298.97M | -70.64%216.47M | -78.53%141.91M | -79.31%92.09M | 12.64%950.72M |
| Operating cost | -36.78%47.3M | 20.13%263.8M | 10.81%200.98M | 9.64%137.18M | 26.40%74.82M | -75.18%219.59M | -74.91%181.38M | -79.79%125.12M | -85.16%59.2M | 27.50%884.78M |
| Operating tax surcharges | 147.52%3.34M | 49.89%8.18M | 51.81%6.25M | 22.62%4.81M | -37.21%1.35M | -72.01%5.46M | -65.59%4.11M | -61.21%3.92M | -64.43%2.15M | 15.71%19.49M |
| Operating expense | 103.35%9.13M | 10.72%30.87M | 6.37%18.16M | 2.45%11.33M | -20.00%4.49M | -2.05%27.88M | -19.73%17.08M | -33.21%11.06M | -21.50%5.61M | 24.24%28.47M |
| Administration expense | 19.42%15.53M | 7.21%55.02M | 29.56%47.78M | 37.35%32.04M | 19.39%13.01M | -10.93%51.33M | -7.00%36.88M | -11.08%23.33M | -12.73%10.89M | 23.36%57.63M |
| Financial expense | 50.56%-8.49M | 29.95%-60.07M | 55.47%-29.71M | 32.44%-33.85M | -493.71%-17.17M | 41.99%-85.76M | 55.99%-66.73M | 37.51%-50.11M | 407.51%4.36M | -8,781.56%-147.85M |
| -Interest expense (Financial expense) | ---- | -79.39%28.16K | -77.24%27.3K | -74.49%22.92K | ---- | -29.75%136.62K | --119.91K | --89.83K | ---- | -71.32%194.48K |
| -Interest Income (Financial expense) | ---- | 31.34%-50.49M | 19.23%-39.36M | -11.40%-30.65M | ---- | -98.08%-73.53M | ---48.74M | ---27.51M | ---- | -145.27%-37.12M |
| Research and development | 3.24%15.12M | -21.00%63.57M | 0.45%43.94M | 6.19%30.36M | 48.23%14.65M | -25.63%80.48M | -53.10%43.75M | -58.75%28.59M | -49.56%9.88M | 74.74%108.21M |
| Credit Impairment Loss | 555.87%1.55M | -1.74%-3.62M | 53.24%-1.38M | 77.37%-500.35K | 138.81%236.68K | -164.96%-3.56M | -169.27%-2.94M | -160.98%-2.21M | -240.19%-609.81K | 261.25%5.48M |
| Asset Impairment Loss | 84.17%-64.26K | 58.76%-22.79M | -20.08%-9.37M | 27.49%-5.57M | 38.61%-406K | 25.21%-55.27M | 10.58%-7.8M | 5.36%-7.68M | 27.72%-661.29K | -541.19%-73.91M |
| Other net revenue | ||||||||||
| Fair value change income | ---257.8K | --257.8K | ---- | ---- | ---- | ---- | -100.98%-64.52K | -101.27%-64.52K | -74.22%1.72M | -92.33%64.52K |
| Invest income | 815.24%1.94M | 100.89%6.79M | 32.65%4.97M | -69.54%1.02M | -174.35%-271.33K | -77.15%3.38M | -60.03%3.74M | -37.62%3.36M | -6.14%364.93K | 6,409.25%14.79M |
| -Including: Investment income associates | -141.97%-693.32K | -187.18%-1.32M | ---637.41K | ---463.41K | ---286.53K | ---459.5K | ---- | ---- | ---- | ---- |
| Asset deal income | -559.20%-328K | -14,881.51%-334.43K | 52.00%-49.76K | 52.39%-49.76K | ---49.76K | --2.26K | ---103.67K | ---104.52K | --0 | --0 |
| Other revenue | -22.20%421.62K | -48.23%15.08M | 53.34%3.82M | -51.53%887.29K | -64.87%541.94K | 66.59%29.14M | -75.23%2.49M | -77.65%1.83M | -63.00%1.54M | 175.71%17.49M |
| Operating profit | -79.30%9.22M | 65.55%193.41M | 9.09%99.37M | 24.17%81.08M | 219.09%44.54M | -87.22%116.82M | -91.25%91.09M | -92.56%65.3M | -97.61%13.96M | -5.40%914.34M |
| Add:Non operating Income | 9,524.86%259.05K | 159.73%1.58M | -99.14%109.49K | -97.69%110.42K | -71.52%2.69K | 5,727.61%608.15K | 1,452.15%12.71M | 491.77%4.77M | 12.24%9.45K | -99.61%10.44K |
| Less:Non operating expense | 747.48%10.63K | -95.75%66.06K | -97.84%7.35K | 5,928.75%4.62K | -99.58%1.25K | -87.52%1.55M | -94.76%340.85K | -100.00%76.56 | -82.94%295.24K | 2,169.19%12.46M |
| Total profit | -78.74%9.47M | 68.21%194.92M | -3.85%99.47M | 15.87%81.18M | 225.77%44.54M | -87.15%115.88M | -90.01%103.46M | -91.96%70.07M | -97.65%13.67M | -6.89%901.9M |
| Less:Income tax cost | -63.72%1.81M | 166.08%28.14M | -4.22%12.84M | 18.07%10.75M | 130.63%5M | -91.76%10.58M | -91.05%13.4M | -92.78%9.1M | -97.52%2.17M | -3.42%128.33M |
| Net profit | -80.64%7.65M | 58.38%166.78M | -3.80%86.64M | 15.54%70.44M | 243.71%39.53M | -86.39%105.3M | -89.83%90.06M | -91.82%60.96M | -97.67%11.5M | -7.44%773.56M |
| Net profit from continuing operation | -80.64%7.65M | 58.38%166.78M | -3.80%86.64M | 15.54%70.44M | 243.71%39.53M | -86.39%105.3M | -89.83%90.06M | -91.82%60.96M | -97.67%11.5M | -7.44%773.56M |
| Less:Minority Profit | -1,013.75%-1.08M | -109.80%-2.74M | -75.37%-2.57M | -171.77%-1.74M | 75.57%-97.02K | -1,762.54%-1.31M | -329.07%-1.47M | -256.76%-639.88K | -137.52%-397.15K | -103.24%-70.12K |
| Net profit of parent company owners | -77.97%8.73M | 59.01%169.52M | -2.53%89.21M | 17.16%72.18M | 233.05%39.63M | -86.22%106.61M | -89.66%91.53M | -91.73%61.6M | -97.58%11.9M | -7.19%773.63M |
| Earning per share | ||||||||||
| Basic earning per share | -78.95%0.08 | 61.00%1.61 | -1.16%0.85 | 18.97%0.69 | 245.45%0.38 | -86.21%1 | -89.63%0.86 | -91.69%0.58 | -97.62%0.11 | -24.64%7.25 |
| Diluted earning per share | -78.95%0.08 | 61.00%1.61 | -1.16%0.85 | 18.97%0.69 | 245.45%0.38 | -86.21%1 | -89.63%0.86 | -91.69%0.58 | -97.62%0.11 | -24.64%7.25 |
| Other composite income | -67.09%84.29K | 189.19%1.4M | -276.22%-1.79M | -18.44%933.32K | -63.81%256.15K | -378.46%-1.57M | -35.59%1.02M | 69.02%1.14M | 5,323.93%707.86K | 92,657.79%563.61K |
| Other composite income of parent company owners | -66.71%83.28K | 182.80%1.3M | -301.73%-1.85M | -10.42%922.63K | -60.73%250.18K | -408.46%-1.56M | -35.59%914.87K | 69.02%1.03M | 5,323.93%637.08K | 92,657.62%507.25K |
| Other composite income of minority owners | -83.06%1.01K | 2,266.63%104.25K | -46.64%54.24K | -90.65%10.7K | -91.57%5.97K | -108.54%-4.81K | -35.59%101.65K | 69.02%114.44K | 5,323.93%70.79K | 92,659.32%56.36K |
| Total composite income | -80.56%7.74M | 62.13%168.18M | -6.84%84.85M | 14.91%71.37M | 225.88%39.79M | -86.60%103.73M | -89.73%91.08M | -91.68%62.11M | -97.53%12.21M | -7.37%774.13M |
| Total composite income of parent company owners | -77.90%8.82M | 62.61%170.81M | -5.49%87.37M | 16.71%73.1M | 218.12%39.88M | -86.43%105.04M | -89.57%92.44M | -91.60%62.63M | -97.45%12.54M | -7.13%774.14M |
| Total composite income of minority owners | -1,085.64%-1.08M | -101.08%-2.64M | -84.45%-2.52M | -228.92%-1.73M | 72.10%-91.05K | -9,426.87%-1.31M | -271.04%-1.37M | -210.41%-525.45K | -130.87%-326.36K | -100.64%-13.76K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | -- | -- | -- | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhonghui Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.